AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01462240 — intervention group
Intervention type: DEVICE
Intervention: LPS Flex Porous Femoral Components
Description: Porous femoral components in total knee arthroplasty
Study NCT02780180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGC001
Study NCT02780180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose capsule manufactured to mimic QGC001 50 mg and 250 mg
Study NCT01040624 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: < 15% risk of + LN
Description: Total of 54 Cobalt gray equivalent (CGE) over 30 treatments to prostate + seminal vesicles (SV), then proton boost total of 23.4-27 CGE over 13-15 treatments to prostate +/- SV. Low dose docetaxel every week during radiation therapy (RT) followed by androgen deprivation therapy for 6 months.
Study NCT03771300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: This program is structured around two central elements, mindfulness and compassion. The sessions combine theory and practice components, using a methodology which priorities the reflection and debate among the students. Regarding theory component, mindfulness and compassion concepts will be set out over the length of the program, in addition to others related to time management, stress, anxiety and the balance between personal life and academic/work life. The practical component of the program consists of mindfulness and self-compassion formal and informal practices under the guidance of a specialized instructor.
Study NCT02788110 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Noninvasive neurally adjusted ventilatory assist (NIV NAVA)
Description: Neurally adjusted ventilatory assist (NAVA) is a mode of ventilation that uses a functional naso/orogastric tube with embedded electrodes which detect diaphragmatic contractions (called the Edi signal). NAVA uses this Edi signal to synchronize ventilator support to the patient's own respiratory efforts and to support these efforts as needed.
Study NCT01040624 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: > 15% risk of + LN
Description: Total of 45 Gy over 25 treatments to prostate + SV + LN, then proton boost total of 32.4-36 CGE over 18-20 treatments to prostate + SV. Low dose docetaxel every week during RT followed by androgen deprivation therapy for 6 months.
Study NCT04498975 — intervention group
Intervention type: OTHER
Intervention: Rurality; Ethnicity; Exercise; Hopelessness
Description: Observational study exploring rurality, ethnicity, exercise and hopelessness patterns cross-sectionally and longitudinally
Study NCT05428306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A1: Ibuprofen/Acetaminophen Fixed dose combination (Laboratorios Silanes S.A. de C.V.)
Description: Formula : 200 mg/ 500 mg Pharmaceutical Form: Tablet Dosage: 400 mg / 1000 mg (2 tablets) Administration way: oral
Study NCT03863665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci
Description: Telemetric home monitoring is a promising strategy to facilitate home BP monitoring after stroke, which should improve adherence and optimize medication to better control BP. Telemetry allows patients with hypertension to monitor their own BP and automatically send the information to a secure website, available to their clinicians to monitor and adjust their treatment.
Study NCT01019070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-650032
Description: Capsules, Oral, 200 mg, BID, 7 Days
Study NCT03410524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simethicone Solution
Description: 200 mg of Simethicone in 3 mL of Simethicone Solution Formulation
Study NCT03410524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 3 mL of water as placebo added to the bowel preparation
Study NCT03292380 — intervention group
Intervention type: OTHER
Intervention: No intervention was included
Study NCT00676013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Integra
Description: Grafting using the Commercial product Integra as a skin substitute over full thickness burn following excision.
Study NCT05428306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A2: Ibuprofen (Motrin®, Pfizer S.A. de C.V.)
Description: A2: Pharmaceutical Form: tablet Dosage: 400 mg (1 tablet) Administration way: oral
Study NCT05428306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A3: Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.)
Description: A3:Pharmaceutical Form: tablet Formula: Acetaminophen 500 mg Dosage: 1000 mg (2 tablets) Administration way: oral
Study NCT00676013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AlloDerm
Description: Grafting using the commercial product AlloDerm as a skin substitute
Study NCT00676013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Homograft
Description: Grafting using homograft as a skin substitute
Study NCT00676013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autograft
Description: grafting using patients own skin from a separate donor site
Study NCT04215640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfidelity (MIFI) catheter
Description: Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Microfidelity (MIFI) catheter equipped with mini-electrodes will be used for ablation in the MIFI group.
Study NCT02015312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epigallocatechin-3-gallate (EGCG)
Description: Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months
Study NCT02015312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months
Study NCT04215640 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ablation catheter
Description: Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Blazer II radiofrequency ablation catheter will be used for ablation in the control group.
Study NCT00858624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: Administration of low dose intravenous ketamine. Dose: 0.075mg/kg over 10 minutes followed by 0.005mg/kg/min over 20 minutes. Given as single infusion.
Study NCT03771300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness condition complemented by VR
Description: The VR is comprised of a Samsung VR goggles, a Samsung Galaxy S6 phone and optional headphones.~In this condition, the instructor is the same as previously but the implementation of VR will be carried out by a psychologist specially trained for the application of these VR scenarios. Prior to the VR use, the psychologist will make sure about the participants´ health.
Study NCT03115762 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: recombinant humanized monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells
Study NCT03115762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASKB1202
Study NCT00965250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-12
Description: 20 mg/kg intravenously once every three weeks
Study NCT01987102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Folinate
Description: The enrolled patients will be treated according to the MAP schedule and will receive the study drug Calcium Folinate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and \[6R\] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) \[6R\] 5,10-methylenetetrahydrofolate dose cohort groups: with \[6R\] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort.
Study NCT01987102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [6R] 5,10-methylenetetrahydrofolate (arfolitixorin)
Description: The enrolled patients will be treated according to the MAP schedule and will receive the study drug \[6R\] 5,10-methylenetetrahydrofolate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and \[6R\] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) \[6R\] 5,10-methylenetetrahydrofolate® dose cohort groups: with \[6R\] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort.
Study NCT02788110 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Description: Nasal intermittent positive pressure ventilation (NIPPV) or noninvasive pressure control ventilation (NIV PC) is a mode of ventilation delivering unsynchronized puffs of air or breaths to a baby through nasal cannulae.
Study NCT00592488 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acetyl-L-Carnitine
Description: Acetyl-L-Carnitine - 4 g IV over 30 minutes, then 8 g iv over the next 12 hours
Study NCT02132819 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Withholding feeds
Description: At least 2 feeds before the transfusion, 2 feeds after the transfusion and feeds during the transfusion are withholded
Study NCT02132819 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: feeding during transfusion
Description: The feeding process will be continued during the transfusion
Study NCT04806074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Evidence-based food-related national and international guidelines were (i) specifically arranged considering the Food Literacy Wheel (Rosas et al., 2021) and personalised materials contained these guidelines were designed, (ii) matched with tailored behaviour change techniques (BCT Taxonomy v1, by Michie et al., XXXX) that indicated how to develop/implement each competence/behaviour, and (iii) digitally delivered weekly. Psychological variables of the Health Action Process Approach model (HAPA; Schwarzer, 2008) were integrated in the intervention, to study potential food literacy's psychological determinants. Weekly introduction videos featuring the lead psychologist were made available. Participants' groups in WhatsApp were built to incentive experience-sharing. Food literacy domains and HAPA determinants were assessed weekly, post-intervention, and in follow-up moments 3-, 6- and 9-months after the intervention.
Study NCT04806074 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparison Group
Description: Food-related guidelines were delivered in a single moment in the first week of the intervention, on their original format and referring their original source (national's and international's entities websites). There was not a thematic for each specific week. No weekly introduction videos or WhatsApp groups existed in this condition. Food literacy domains and HAPA determinants were assessed weekly, post-intervention, and in follow-up moments 3-, 6- and 9-months after the intervention.
Study NCT05065788 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: data collection
Study NCT02109328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: SINGLE-ARM, SINGLE-DRUG PHASE: Alisertib will be given PO in a dosage of 50 mg BID for 7 Days (Days 1-7) of each 21 day treatment cycle.~In the randomized phase, Experimental arm will consist of the following drugs:~Alisertib will be given PO in a dosage of 40 mg twice daily on days 1-3, 8-10 and 15-17 of a 28 day cycle.~Paclitaxel: 60 mg/m2 over 60 minutes on Days 1, 8, and 15 in a 28-day cycle.
Study NCT02109328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Placebo will be given PO. Paclitaxel will be infused at the dose of 80 mg/m2 IV over a period of 60 minutes on Days 1, 8, and 15 in a 28-day cycle.
Study NCT02109328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Placebo will be given PO. Paclitaxel will be infused at the dose of 80 mg/m2 IV over a period of 60 minutes on Days 1, 8, and 15 in a 28-day cycle.
Study NCT00214539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchial Thermoplasty with the Alair System
Description: Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.
Study NCT00214539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.
Study NCT03740854 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Controlled Ventilation
Description: Patients will be ventilated with a pressure level which supplies a tidal volume corresponding 8ml/kg, 12 breaths per minute, 1/2 inspiration/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
Study NCT03740854 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volume Controlled Ventilation
Description: Patients will be ventilated with a tidal volume which corresponds 8ml/kg, 12 breaths per minute, 1/2 inspirastion/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
Study NCT04494620 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visual Inspection of Oral Cavity for Precancers and Cancer
Description: Participants were invited for 3 rounds of oral cavity cancer screening, conducted 3-years apart. Screening was conducted by health workers trained to perform visual inspection of the oral mucosa and identify potential precancerous lesions or oral cancer. Lesions found were referred to a weekly clinic for further evaluation by dentists and oncologists with experience in the diagnosis of oral lesions. Oral precancerous lesions were surgically excised whenever possible and those with confirmed oral cancer were referred for appropriate treatment with surgery, radiotherapy, and/or chemotherapy.
Study NCT03771300 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: This condition is based on the Progressive Muscle Relaxation.The relaxation program include training 16 muscle groups during the initial sessions, 7 muscle groups during the intermediate sessions, 4 muscle groups later and a only recall relaxation in the final session.This program is complemented with visualizations, as it was originally proposed by Jacobson (1938).
Study NCT01861509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP-C1
Description: BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
Study NCT01123005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: radiation calculated per patient
Study NCT01123005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF5
Description: 10 mCi, IV
Study NCT01123005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbogen
Description: Calculated per patient
Study NCT01123005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate
Study NCT03536637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMT310
Description: Topical Powder
Study NCT02109328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablets
Study NCT05320029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable Powered Articulating Endoscopic Linear Cutter Stapler
Description: Using the Disposable Powered Articulating Endoscopic Linear Cutter Stapler according to routine treatment
Study NCT03536637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide
Description: Liquid Diluent
Study NCT03536637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Topical Powder
Study NCT03536637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Topical Powder
Study NCT04392856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP)
Description: The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders for Homeless Women. The protocol contains five modules: (1) mindful emotion awareness, (2) cognitive flexibility, (3) countering emotional behaviors, (4) recognizing and confronting physical sensations, and (5) emotion exposures. This adaptation of Unified Protocol is organized in twelve sessions: Emotional disorders and emotional regulation; Motivation for change; Understanding the role of emotions; Mindful emotion awareness, Cognitive flexibility, Understanding and confronting physical sensations, Countering emotional behaviors, Emotional avoidance, Emotion exposure; Achievement recognition and look to the future; and Relapse prevention and closure.
Study NCT03081026 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bilateral hip to ankle x-ray, exam and strength testing.
Description: Only an X-Ray is performed and reviewed to identify any growth disturbances.
Study NCT06385483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Given PO
Study NCT06385483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06385483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06385483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06385483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT05320029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECHELON Flex Powered Articulating Endoscopic Linear Cutters
Description: Using the ECHELON Flex Powered Articulating Endoscopic Linear Cutters according to routine treatment
Study NCT03855735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeamBaby Online Communication Training (IG1) and TeamBaby Web-App Communication Training (IG2)
Description: The developed short manual for the teaching of different communication models competences will enable those who have been arbitrarily assigned to the intervention group and their relatives to develop secure communication competences (Phase 2). In Phase 3, the intervention group will have access to the digital app.
Study NCT02921607 — intervention group
Intervention type: OTHER
Intervention: Observational group
Description: Participants will be asked to complete a questionnaire prior to discharge and 3 months later to follow up
Study NCT01767922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extramel 10 mg - 140 UI SOD
Description: Subjects took one capsule of Extramel® 140 IU, or its corresponding placebo, daily over 12 weeks.~Each volunteer was seen for the 3 visits:~* visit V1, so-called inclusion visit (D0),~* visit V2 at 28 days, tolerance of +/- 3 days, (D28) and~* visit V3 at 84 days, tolerance of +/- 3 days, (D84).
Study NCT01767922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Excipient only
Study NCT03287388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Rocuronium
Description: Phase 1: The patient will undergo a routine MRI-abdomen without neuromuscular blockade: TOF ratio =1.
Study NCT03287388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (moderate NMB)
Description: Phase 2: Rocuronium will be titrated to a moderate NMB (TOF 1-3), monitored by TOF-watch. When an adequate moderate NMB is achieved, the patient will undergo a second MRI-abdomen.
Study NCT03287388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium (deep NMB)
Description: Phase 3: The patient receives a bolus of 1.2 mg/kg rocuronium (adjusted to ideal body weight), to assure a deep or intense NMB (PTC 0-1). Then the patient will undergo the final, third MRI scan of the abdomen.
Study NCT05300165 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Beer
Description: A daily beer will be consumed by the participants during a total of 6 weeks, changing every 2 weeks from alcohol-free lager beer, lager beer and dark beer
Study NCT03800498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH Education
Description: DASH health education about general knowledge of DASH diet Plan and lifestyle modification
Study NCT01225029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amount of total fluids
Description: Term neonates receive either total fluids of 60 mL/kg/day (standard) or 40 mL/kg/day (restricted) on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day (standard) or 60 mL/kg/day (restricted) on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.